The Catheter Related Bloodstream Infection (CRBSI) market is projected to experience substantial growth, reaching an estimated value of around $2.5 billion by 2033, up from $1.5 billion in 2023. This and rise represents a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2024 – 2033. The escalating occurrence of CRBSIs, primarily among long-term catheterized patients such as those receiving hemodialysis, in intensive care, or undergoing treatments requiring Central Venous Catheters (CVCs), acts as a key market growth driver. CRBSIs, which often lead to severe complications and result in expensive treatments, are a significant concern in healthcare environments.
In December 2022, CorMedix initiated a comprehensive study that amalgamated clinical data and claims from patients undergoing hemodialysis with CVCs. This substantial analysis aimed to design therapeutic solutions for preventing and treating CRBSIs, and it accentuated the necessity to promptly address CRBSIs.
Moreover, as patient needs for CVCs surge, a corresponding demand for efficient infection prevention solutions generates market growth. With an increased awareness of healthcare-associated infections (HAIs) and a recognized requirement for advanced technologies to handle these complications, the opportunities for novel medical devices and antimicrobial coatings that significantly mitigate the risk of infections are expanding. With emerging trends spotlighting the importance of preventive therapies, including antiseptic locks and catheter modifications, market prospects are further enhanced.
The echinocandin segment was a market leader in 2023, recording a 45.5% share due to its amplified efficacy against fungal infections, a common challenge in catheter-related infections. Meanwhile, the rise in hospital-acquired infections and growing immunocompromised demographics further bolster the demand for echinocandins.
The oral formularies boasted a substantial 55.8% market share, driven by a growing demand for patient convenience and alternatives to invasive treatments. The rise in the application of oral drugs for treating catheter-related bloodstream infections, bolstered by advancements in oral drug formulations and an increasing trend toward home healthcare, shows marked promise for this segment’s growth.
Hospitals play an integral part in treating infections, and thus the hospital pharmacies segment is growing at an accelerated rate. The segment’s growth comes as the growing occurrence of catheter-related infections and incremental complexity within patient care amplify the demand for readily available medications from hospitals’ repositories.
High costs surrounding infection prevention and treatment may restrain market growth. Investments required for advanced medical devices, continuous monitoring, and specialized treatments may strain healthcare budgets. Additionally, economically strained regions may find it challenging to implement optimal prevention strategies, further hampering the market’s growth.
Positive growth factors include a rise in availability of innovative treatments and in clinical research activities. The latter may result in the development of new treatments and technologies. Macroeconomic factors such as healthcare policy changes, changes in hospital settings, and increasing awareness about the risks of catheter-related infections can also shape the market’s trajectory.
Furthermore, collaborations and partnerships enhance growth in the market, with companies joining forces to develop innovative solutions. As healthcare providers adopt more effective infection prevention strategies and with the advent of continuous advancements in treatment protocols, market demand for these solutions is expected to increase.
Regional trends depict North America as a dominating force in the market due to advancements in technologies and risen awareness of healthcare predicaments caused by CRBSIs. The Asia-Pacific region is expected to experience the highest CAGR during the forecast period due to improvements in healthcare infrastructure, particularly in countries like India and China.
Key players in the market leverage several strategies, including enhancing product offerings, expanding global presence, and strengthening partnerships with healthcare providers, to gain a competitive edge.
Source: https://market.us/report/catheter-related-bloodstream-infection-market/